PPI therapy

PPI plus aspirin for secondary cardiovascular disease prevention

Article metrics

Aspirin is widely used for cardiovascular disease prevention, but is associated with adverse gastrointestinal effects, which reduce the likelihood of treatment compliance. A new study shows that PPI co-therapy reduces gastrointestinal and cardiovascular events, and is cost-effective at generic price for treating patients who take aspirin for secondary cardiovascular disease prevention.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Saini, S. D., Schoenfeld, P., Fendrick, A. M. & Scheiman, J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch. Intern. Med. 168, 1684–1690 (2008).

  2. 2

    Saini, S. D., Fendrick, A. M. & Scheiman, J. M. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment. Pharmacol. Ther. 34, 243–251 (2011).

  3. 3

    Baigent, C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).

  4. 4

    Chan, F. K. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352, 238–244 (2005).

  5. 5

    Lai, K. C. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033–2038 (2002).

  6. 6

    Sung, J. J. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152, 1–9 (2010).

  7. 7

    Melloni, C. et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am. J. Cardiol. 104, 175–181 (2009).

  8. 8

    Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118, 1894–1909 (2008).

  9. 9

    Pant, C., Madonia, P. & Minocha, A. Does PPI therapy predispose to Clostridium difficile infection? Nat. Rev. Gastroenterol. Hepatol. 6, 555–557 (2009).

  10. 10

    Earnshaw, S. R., Scheiman, J., Fendrick, A. M., McDade, C. & Pignone, M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch. Intern. Med. 171, 218–225 (2011).

Download references

Author information

Correspondence to Francis K. L. Chan.

Ethics declarations

Competing interests

F. K. L. Chan has received paid lecture fees from Pfizer, Takeda and AstraZeneca. S.C Ng has received paid lecture fees from Ferring.

Rights and permissions

Reprints and Permissions

About this article